

Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024

<https://marketpublishers.com/r/G0A5326E8E1EN.html>

Date: April 2018

Pages: 140

Price: US\$ 2,400.00 (Single User License)

ID: G0A5326E8E1EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024” Report Highlights:

General Working Mechanism of Personalized Cancer Vaccine

Relevance of Biomarkers In Personalized Vaccines

Developmental Cost Analysis of a Personalized Cancer Vaccine

Advancements in the Personalized Cancer Vaccine

Personalized Cancer Vaccine Market Analysis by Cancer

Vaccines are therapeutics that helps protect body from disease. They unusually work by enhancing the ability of immune cells to recognize, target and destroy entities that might be harmful for the body. A Key immunotherapeutic product that has grabbed immense attention in the healthcare segment is the cancer vaccine; which is considered to be one of the most promising ways to treat, cure and prevent cancer.

Recent research proved that the genetic makeup of an individual has a significant impact on the overall therapeutic outcome of the administered therapeutic, which has led researchers to follow a more customized approach in vaccine manufacture to provide the best therapeutic output in patients suffering from a complex disease such as

cancer. This customized approach would be more specifically targeted according to the patient's need which is bound to enhance the overall therapeutic outcome.

Currently there are two types of cancer vaccines available - preventive and therapeutic. Therapeutic vaccines treat an existing cancer by enhancing the body's natural immune system to recognize, target and destroy tumor cells. Provenge for prostate cancer is the only therapeutic vaccine approved for metastatic prostate cancer in the US.

Unlike cancer therapeutic vaccine, a preventive cancer vaccine is given to provide immunity against viruses that might cause cancer. The only preventative vaccines that have been successfully commercialized at a global level are the human papillomavirus vaccine and hepatitis B virus vaccine.

The cancer therapeutic segment is currently anticipated to be worth more than US\$ 100 Billion. With rapid advancement in the immunotherapy segment, almost 60% of the market will be dominated by some immunotherapeutic product by 2024, thus forming the backbone of the global cancer therapy market. This presents an excellent opportunity for an innovative product such as the personalized cancer vaccine.

Genetic sequencing of patient's tumor cell for neo-antigen is a vital step in the manufacture of personalized cancer vaccine. About a decade ago, the cost for genetic sequencing for an individual was highly expensive, costing about US\$ 300,000. Fortunately, the advancement in genetic sequencing techniques, emergence of advanced computing and artificial intelligence has made it a very affordable and faster process which is a major driving factor for the personalized cancer vaccine market.

The US is currently the leading market for personalized cancer vaccine, followed by the European Union. The early launch and impressive adoption of existing preventive and therapeutic cancer vaccine indicates that the US is bound to remain the dominant market for at least a decade. The involvement of regions like Japan, South Korea and China indicates it to be a competitive market in the future. Most of the cancer vaccines under development are focused on the treatment of deadly and highly prevalent cancers such as Melanoma, breast cancer, lung cancer, prostate cancer and Cervical Cancer.

Kuick Research Report on the personalized cancer vaccine market provides a detailed insight into the current status of the segment with special emphasis on the clinical innovations governing the market. The report also highlights the clinical relevance of personalized cancer vaccine, trends and recent advances that will impact the growth of

the market. Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2024.

Contents

1. PERSONALIZED CANCER VACCINE: PROMISING CANCER THERAPEUTICS OF THE FUTURE

- 1.1 The Possibility of a Cancer Vaccine
- 1.2 Cancer Vaccines - An Insight into its Current Clinical Status

2. GENERAL WORKING MECHANISM OF PERSONALIZED CANCER VACCINE

- 2.1 Entities of A personalized Cancer Vaccine & Their Respective Roles
 - 2.1.1 Tumor Neo - Antigens
 - 2.1.2 Human Leukocyte Antigen
- 2.2 Personalized Cancer Vaccine in Action
- 2.3 Pharmacogenomics towards Genomic Polymorphism
- 2.4 Somatic Mutations in Cancer Pharmacogenomics

3. RELEVANCE OF BIOMARKERS IN PERSONALIZED VACCINES

- 3.1 Pharmacogenomic Biomarkers
- 3.2 Prognostic & Predictive Biomarkers
- 3.3 Immune Checkpoint Biomarkers

4. MANUFACTURING PROCESS & COST ANALYSIS OF A PERSONALIZED CANCER VACCINE

- 4.1 Pre - Manufacturing Cost Analysis
- 4.2 Manufacturing Cost Analysis of Personalized Cancer Vaccine
 - 4.2.1 Capital Cost
 - 4.2.2 Cost of Raw Materials
 - 4.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
 - 4.2.4 Factory & Administrative Overheads
 - 4.2.5 Filling & Packaging
- 4.3 Personalized Cancer Vaccine Cost per Patient

5. CURRENT MARKET TRENDS & ADVANCEMENTS IN THE PERSONALIZED CANCER VACCINE SEGMENT

- 5.1 Breakthrough Research Improving the Outcome of Future Personalized Cancer

Vaccine

5.2 Rising Investments in the Personalized Cancer Vaccine Market

5.3 Use of mRNA for the Development of Personalized Cancer Vaccine

5.4 Collaborations & Ventures Ensure Stable Funding to the Personalized Cancer Vaccine Market

5.5 Advancement in DNA Sequencing Technology to Drive the Personalized Cancer Vaccine Market

6. GLOBAL - PERSONALIZED CANCER VACCINE MARKET ANALYSIS BY CANCER TYPE

6.1 Melanoma

6.2 Lung Cancer

6.3 Breast Cancer

6.4 Colorectal Cancer

6.5 Leukemia

6.6 Prostate Cancer

6.7 Cervical Cancer

6.8 Glioblastoma (Brain Tumor)

7. NEW AVENUES & OPPORTUNITIES FOR PERSONALIZED CANCER VACCINE DEVELOPMENT

7.1 Commercial Insights into the Personalized Cancer Vaccine Pipeline

7.2 Opportunities in the Emerging Market

8. PORTER'S FIVE FORCE ANALYSIS OF THE PERSONALIZED CANCER VACCINE MARKET

8.1 Bargaining Power of Suppliers

8.2 Bargaining Power of Buyer

8.3 Threats of Substitute Products

8.4 Threat of New Entrants

8.5 Rivalry Among the Existing Competitors

9. DRIVING FACTORS OF THE PERSONALIZED CANCER VACCINE MARKET

9.1 Increasing Need for Personalized Cancer Vaccine Production

9.2 Alarming Increase in the Number of Cancer Incidences

9.3 Cancer Heterogenetic Environment

9.4 High Level of Specificity

9.5 Assistance from Government

9.6 Improvement in Genome Sequencing Techniques

9.7 Robust Clinical Pipeline Under Development

10. MAJOR CHALLENGES TO THE PERSONALIZED CANCER VACCINE MARKET

10.1 Scientific & Technical Challenges in Developing a Personalized Cancer Vaccine

10.2 Commercialization Challenges

11. GLOBAL PERSONALIZED CANCER VACCINE MARKET FUTURE OUTLOOK

12. COMPETITIVE LANDSCAPE

12.1 Advaxis Inc.

12.2 Avax Technologies

12.3 BioNtech AG

12.4 Celldex

12.5 CureVac AG

12.6 Genetech

12.7 Genocea

12.8 Gristone Oncology

12.9 ISA Pharmaceuticals

12.10 Merck

12.11 Moderna Therapeutics

12.12 Neon Therapeutics

12.13 Personalis

List Of Figures

LIST OF FIGURES

- Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
- Figure 1-2: Advantages of Targeting Neo – Antigens in Cancer Vaccine Production
- Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
- Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
- Figure 2-3: The Sources of Pharmacological & Pharmacogenetic Variability's
- Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
- Figure 3-2: Roadmap of Development of Predictive Biomarkers
- Figure 3-3: High Throughput Immune Assessment for Biomarker Discovery
- Figure 4-1: General Overview of Personalized Cancer Vaccine Production
- Figure 4-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US\$), 2018
- Figure 4-3: Gardasil - Annualized Capital Cost of Production (US\$ Million), 2018
- Figure 4-4: Cervarix - Annualized Capital Cost of Production (US\$ Million), 2018
- Figure 4-5: Gardasil - Raw Material Cost Analysis (US\$ Million), 2018
- Figure 4-6: Cervarix - Raw Material Cost Analysis (US\$ Million), 2018
- Figure 4-7: Gardasil – Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US\$ Million), 2018
- Figure 4-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US\$ Million), 2018
- Figure 4-9: Gardasil - Factory & Administrative Overheads (US\$ Million), 2018
- Figure 4-10: Cervarix - Factory & Administrative Overheads (US\$ Million), 2018
- Figure 4-11: Gardasil – Manufacturing Cost per single Dose (US\$), 2018
- Figure 4-12: Cervarix - Manufacturing Cost per single Dose (US\$), 2018
- Figure 4-13: Personalized Cancer Vaccine - Treatment Cost (US\$/Patient), 2018
- Figure 4-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
- Figure 4-15: Gardasil & Gardasil 9 - Cost Analysis (US\$), 2018
- Figure 5-1: Trends & Advancement in the Personalized Cancer Vaccine Segment
- Figure 5-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US\$ Million), 2018
- Figure 6-1: Alteration in CDKN2A Mechanism
- Figure 6-2: Global - Melanoma & Non – Melanoma Cancer Incidence (000'), 2018
- Figure 6-3: Global - Melanoma Prevalence by Region (%), 2018
- Figure 6-4: Global - Lung Cancer Incidence (in 000'), 2018
- Figure 6-5: Global – Lung Cancer Prevalence by Region (%), 2018
- Figure 6-6: Global - Breast Cancer Incidence (000'), 2018

- Figure 6-7: Global - Breast Prevalence by Region (%), 2018
- Figure 6-8: Global - Colorectal Cancer Incidence (000'), 2018
- Figure 6-9: Global - Colorectal Cancer Market Size (%), 2018
- Figure 6-10: Global - Leukemia Incidence (000'), 2018
- Figure 6-11: Global - Leukemia Market Size (%), 2018
- Figure 6-12: Global - Prostate Cancer Incidence (000'), 2018
- Figure 6-13: Global - Prostate Cancer Prevalence by Region (%), 2018
- Figure 6-14: Provenge - Cost Analysis (US\$/Month)
- Figure 6-15: Global - Cervical Cancer Incidence (000'), 2018
- Figure 6-16: Global - Cervical Cancer prevalence by Region (%), 2018
- Figure 7-1: Global - Oncology Market Size by Region (%), 2017
- Figure 8-1: Porter's Five Force Analysis - Overview
- Figure 9-1: Driving Factors of the Personalized Cancer Vaccine Market
- Figure 9-2: Global - Most Common Types of Cancer by Prevalence, 2018
- Figure 9-3: Decrease in the Cost of Human Genome Sequencing (US\$/Patient), 2018
- Figure 9-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
- Figure 10-1: Scientific Limitations in Personalized Cancer Vaccine Development
- Figure 11-1: Global - Gardasil Sales Forecast (US\$ Billion), 2018 -2024
- Figure 11-2: Cervarix – Future Sales Forecast (US\$ Billion), 2018 – 2024
- Figure 11-3: Global - Personalized Cancer Vaccine Market Opportunity (US\$ Billion), 2018 – 2024

List Of Tables

LIST OF TABLES

Table 5-1: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer

Table 5-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia

COMPANIES MENTIONED

Advaxis Inc., Avax Technologies, BioNtech AG, Celldex, CureVac AG, Genetech, Genocea, Gristone Oncology, ISA Pharmaceuticals, Merck, Moderna Therapeutics, Neon Therapeutics, Personalis

I would like to order

Product name: Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024

Product link: <https://marketpublishers.com/r/G0A5326E8E1EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0A5326E8E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

